Sign In
Buy DOCS
Doximity Earnings Calls
| Release date | May 13, 2026 |
| EPS estimate | $0.280 |
| EPS actual | $0.260 |
| EPS Surprise | -7.14% |
| Revenue estimate | 144.034M |
| Revenue actual | 145.372M |
| Revenue Surprise | 0.93% |
| Release date | Feb 05, 2026 |
| EPS estimate | $0.440 |
| EPS actual | $0.460 |
| EPS Surprise | 4.55% |
| Revenue estimate | 181.628M |
| Revenue actual | 185.053M |
| Revenue Surprise | 1.89% |
| Release date | Nov 06, 2025 |
| EPS estimate | $0.379 |
| EPS actual | $0.450 |
| EPS Surprise | 18.83% |
| Revenue estimate | 157.902M |
| Revenue actual | 168.525M |
| Revenue Surprise | 6.73% |
| Release date | Aug 07, 2025 |
| EPS estimate | $0.302 |
| EPS actual | $0.360 |
| EPS Surprise | 19.36% |
| Revenue estimate | 139.53M |
| Revenue actual | 145.913M |
| Revenue Surprise | 4.57% |
Last 4 Quarters for Doximity
Below you can see how DOCS performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Aug 07, 2025 |
| Price on release | $58.55 |
| EPS estimate | $0.302 |
| EPS actual | $0.360 |
| EPS surprise | 19.36% |
| Date | Price |
|---|---|
| Aug 01, 2025 | $57.33 |
| Aug 04, 2025 | $58.30 |
| Aug 05, 2025 | $57.93 |
| Aug 06, 2025 | $58.13 |
| Aug 07, 2025 | $58.55 |
| Aug 08, 2025 | $66.58 |
| Aug 11, 2025 | $61.83 |
| Aug 12, 2025 | $61.82 |
| Aug 13, 2025 | $64.02 |
| 4 days before | 2.13% |
| 4 days after | 9.34% |
| On release day | 13.71% |
| Change in period | 11.67% |
| Release date | Nov 06, 2025 |
| Price on release | $62.58 |
| EPS estimate | $0.379 |
| EPS actual | $0.450 |
| EPS surprise | 18.83% |
| Date | Price |
|---|---|
| Oct 31, 2025 | $66.00 |
| Nov 03, 2025 | $66.95 |
| Nov 04, 2025 | $65.82 |
| Nov 05, 2025 | $63.99 |
| Nov 06, 2025 | $62.58 |
| Nov 07, 2025 | $54.29 |
| Nov 10, 2025 | $52.53 |
| Nov 11, 2025 | $52.72 |
| Nov 12, 2025 | $50.96 |
| 4 days before | -5.18% |
| 4 days after | -18.57% |
| On release day | -13.25% |
| Change in period | -22.79% |
| Release date | Feb 05, 2026 |
| Price on release | $33.32 |
| EPS estimate | $0.440 |
| EPS actual | $0.460 |
| EPS surprise | 4.55% |
| Date | Price |
|---|---|
| Jan 30, 2026 | $37.47 |
| Feb 02, 2026 | $37.29 |
| Feb 03, 2026 | $34.85 |
| Feb 04, 2026 | $35.25 |
| Feb 05, 2026 | $33.32 |
| Feb 06, 2026 | $27.73 |
| Feb 09, 2026 | $27.50 |
| Feb 10, 2026 | $27.24 |
| Feb 11, 2026 | $25.96 |
| 4 days before | -11.08% |
| 4 days after | -22.09% |
| On release day | -16.78% |
| Change in period | -30.72% |
| Release date | May 13, 2026 |
| Price on release | $23.39 |
| EPS estimate | $0.280 |
| EPS actual | $0.260 |
| EPS surprise | -7.14% |
| Date | Price |
|---|---|
| May 07, 2026 | $26.03 |
| May 08, 2026 | $25.98 |
| May 11, 2026 | $26.26 |
| May 12, 2026 | $26.45 |
| May 13, 2026 | $23.39 |
| May 14, 2026 | $18.01 |
| May 15, 2026 | $18.97 |
| May 18, 2026 | $19.58 |
| May 19, 2026 | $19.26 |
| 4 days before | -10.14% |
| 4 days after | -17.66% |
| On release day | -23.00% |
| Change in period | -26.01% |
Doximity Earnings Call Transcript Summary of Q1 2026
Doximity reported a stronger-than-expected Q1 FY2026: revenue of $145.9M (+15% YoY) and adjusted EBITDA of $79.8M (55% margin). Engagement and network metrics hit record highs across quarterly, monthly and daily active users; AI tools grew >5x YoY. The company launched a HIPAA‑compliant AI Scribe (beta tested by >10,000 clinicians) with >75% weekly retention and plans telehealth integration. Doximity closed the Pathway acquisition (initial cash $26M plus up to $37M in equity) to bolster clinical-reference AI; Pathway technology has industry-leading accuracy and has already been integrated into Doximity GPT. Q2 revenue guide of $157–158M and full‑year revenue guide raised to $628–636M (midpoint ≈ 11% growth); adjusted EBITDA guide $341–349M (≈55% margin). Free cash flow rose 52% YoY to $60.1M; cash balance ~$841M and $302M remaining in the buyback program after $122.3M repurchases in Q1. Management emphasizes broad-based upsell strength across pharma, health systems and SMBs, continued measured approach to back-half bookings given policy uncertainty, and a deliberate push to make AI the company’s “third act” while keeping physician privacy and clinician control central.
